Back to Search
Start Over
ARF4-mediated retrograde trafficking as a driver of chemoresistance in glioblastoma.
- Source :
-
Neuro-oncology [Neuro Oncol] 2024 Aug 05; Vol. 26 (8), pp. 1421-1437. - Publication Year :
- 2024
-
Abstract
- Background: Cellular functions hinge on the meticulous orchestration of protein transport, both spatially and temporally. Central to this process is retrograde trafficking, responsible for targeting proteins to the nucleus. Despite its link to many diseases, the implications of retrograde trafficking in glioblastoma (GBM) are still unclear.<br />Methods: To identify genetic drivers of TMZ resistance, we conducted comprehensive CRISPR-knockout screening, revealing ADP-ribosylation factor 4 (ARF4), a regulator of retrograde trafficking, as a major contributor.<br />Results: Suppressing ARF4 significantly enhanced TMZ sensitivity in GBM patient-derived xenograft (PDX) models, leading to improved survival rates (P < .01) in both primary and recurrent lines. We also observed that TMZ exposure stimulates ARF4-mediated retrograde trafficking. Proteomics analysis of GBM cells with varying levels of ARF4 unveiled the influence of this pathway on EGFR signaling, with increased nuclear trafficking of EGFR observed in cells with ARF4 overexpression and TMZ treatment. Additionally, spatially resolved RNA-sequencing of GBM patient tissues revealed substantial correlations between ARF4 and crucial nuclear EGFR (nEGFR) downstream targets, such as MYC, STAT1, and DNA-PK. Decreased activity of DNA-PK, a DNA repair protein downstream of nEGFR signaling that contributes to TMZ resistance, was observed in cells with suppressed ARF4 levels. Notably, treatment with DNA-PK inhibitor, KU-57788, in mice with a recurrent PDX line resulted in prolonged survival (P < .01), highlighting the promising therapeutic implications of targeting proteins reliant on ARF4-mediated retrograde trafficking.<br />Conclusions: Our findings demonstrate that ARF4-mediated retrograde trafficking contributes to the development of TMZ resistance, cementing this pathway as a viable strategy to overcome chemoresistance in GBM.<br /> (© The Author(s) 2024. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.)
- Subjects :
- Humans
Animals
Mice
Temozolomide pharmacology
Antineoplastic Agents, Alkylating pharmacology
Protein Transport
Tumor Cells, Cultured
ErbB Receptors metabolism
ErbB Receptors genetics
Cell Proliferation
Cell Line, Tumor
Signal Transduction
Gene Expression Regulation, Neoplastic
Glioblastoma metabolism
Glioblastoma pathology
Glioblastoma drug therapy
Glioblastoma genetics
Drug Resistance, Neoplasm
Brain Neoplasms metabolism
Brain Neoplasms pathology
Brain Neoplasms drug therapy
Brain Neoplasms genetics
Xenograft Model Antitumor Assays
ADP-Ribosylation Factors metabolism
ADP-Ribosylation Factors genetics
Subjects
Details
- Language :
- English
- ISSN :
- 1523-5866
- Volume :
- 26
- Issue :
- 8
- Database :
- MEDLINE
- Journal :
- Neuro-oncology
- Publication Type :
- Academic Journal
- Accession number :
- 38506351
- Full Text :
- https://doi.org/10.1093/neuonc/noae059